Try it
Pharmacology · Anticancer drugs: toxicity prevention
Sample itemA patient receiving high-dose cyclophosphamide develops haematuria. Which drug is given to prevent this complication, and how does it work?
Original practice item, not a recalled exam question. Nothing here is recorded.
The answer and the reasoning
B. Mesna, which binds the urotoxic metabolite acrolein in the bladder
Cyclophosphamide is metabolised to acrolein, which damages the bladder urothelium and causes haemorrhagic cystitis. Mesna is excreted in urine and neutralises acrolein by its sulfhydryl group. Hydration also helps. Ifosfamide has the same risk.
Option by option
A. Leucovorin, which bypasses dihydrofolate reductase
Leucovorin rescues cells from methotrexate toxicity.
B. Mesna, which binds the urotoxic metabolite acrolein in the bladder (correct)
Correct. Mesna's thiol group binds acrolein in the urine.
C. Dexrazoxane, which chelates iron
Dexrazoxane reduces doxorubicin cardiotoxicity.
D. Amifostine, which chelates platinum
Amifostine is a cytoprotective agent used with cisplatin for renal and other toxicity, not for cystitis.
Source note: Original NextPrep sample item — pending expert review. This item is original practice material awaiting independent expert review, so confirm important facts in a standard textbook.
More Pharmacology questions
- Emergency drugsA patient develops stridor, wheeze and hypotension minutes after an injection. What is t…
- AntiepilepticsWhat is the preferred first-line drug for a patient in generalised convulsive status epi…
- AntimicrobialsWhich drug can cause a disulfiram-like reaction when taken with alcohol?
- AntiepilepticsWhich drug is preferred for uncomplicated childhood absence seizures?